A 5
Alternative Names: A5Latest Information Update: 17 Dec 2002
At a glance
- Originator Angstrom Pharmaceuticals
- Class
- Mechanism of Action Angiogenesis inhibitors; Urokinase-type plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 May 1999 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 May 1999 New profile